Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT06163365 Recruiting - Lynch Syndrome Clinical Trials

Inherited Cancer Early Diagnosis (ICED) Study

ICED
Start date: July 26, 2022
Phase:
Study type: Observational [Patient Registry]

ICED is a prospective sample collection research study, aiming to develop or validate a blood/urine biomarker which could potentially detect cancers early in individuals at high risk of developing cancers, due to certain germline alterations.

NCT ID: NCT06163261 Recruiting - Clinical trials for Non-functioning Pituitary Adenoma

Individualized Physical Activity or Patients With Non Functioning Pituitary Adenoma

Start date: February 27, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about physical activity's effect on health in people who have had surgery of a non-functioning pituitary adenoma. The main questions it aims to answer are: - Do physical activity increase quality of life? - Do physical activity increase general health, cardiovascular fitness, self-efficacy and muscle strength and reduce fatigue and cardiovascular risk profile? Participants will at the start of the the study, at 6 months follow up and 12 months follow up: - Fill out health surveys - Perform a cycling test, hand strength test, chair stand test and wear and accelerometer for a week - Undergo a dual energy X-ray absorptiometry to measure muscle and fat mass - Leave blood samples Researchers will compare those who are randomized to the intervention and see a physiotherapist to get an individualized and person-centred prescription of physical activity plan and those who are randomized not to be in the intervention to see if physical activity increases quality of life and general health.¨.

NCT ID: NCT06163040 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Start date: December 22, 2023
Phase:
Study type: Observational

This observational study aimed to assess the safety of elotuzumab when used in combination with pomalidomide and dexamethasone for the treatment of relapsed and refractory multiple myeloma (RRMM) in participants who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The study will also assess the safety of elotuzumab when used in combination with lenalidomide and dexamethasone in RRMM participants who had received one to three prior therapies.

NCT ID: NCT06162858 Recruiting - Healthy Clinical Trials

Reaching Motion During Functional Activities

REACHRSA
Start date: October 15, 2023
Phase: N/A
Study type: Interventional

Taking and moving objects is essential. When this becomes difficult, it affects daily functioning. This study aims to determine movement patterns, at the level of the shoulder, during different functional movements in elderly people aged 60 years and older. Movement patterns of people without shoulder problems and patients with a reverse shoulder prosthesis will be compared. These insights can contribute to improving functional rehabilitation in patients with a reverse shoulder prosthesis (RSA).

NCT ID: NCT06162767 Recruiting - Clinical trials for Esophagogastric Junction Carcinoma

Cancer of Esophagogastric Junction: Optimized Sweet Versus Ivor-Lewis

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

This study is being done to see whether Optimized Sweet Procedure is superior than the Ivor-Lewis Procedure Esophagectomy with better long-term outcome and acceptable postoperative short-term outcome or not.

NCT ID: NCT06162546 Recruiting - Proteinuria Clinical Trials

ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank

Start date: January 1, 2023
Phase:
Study type: Observational [Patient Registry]

Nephrotic syndrome is the clinical phenotype of a heterogeneous group of glomerular diseases that may present with varying degrees of urinary protein loss (proteinuria), dysproteinemia in the blood, fluid retention and impaired renal function. The AustRian RESistanT NEPHROtic Syndrome Treatment Response RegIStry and Biobank (ARREST-NEPHROSIS) sets out to achieve the following goals, as typical categories of rare disease registries 1. Obtaining real world data on practice patterns and outcomes 2. Networking between affected patients, families, and clinicians. 3. Establish a patient base for facilitated recruitment in studies of drugs, medical devices, and products 4. Development of a Biobank to enable research of potential biomarkers and therapy or disease courses

NCT ID: NCT06162377 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Start date: January 10, 2024
Phase: Phase 4
Study type: Interventional

To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks before surgery.

NCT ID: NCT06162286 Recruiting - Clinical trials for Community-acquired Bacterial Pneumonia

A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP

public
Start date: November 17, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to show that in Chinese adults with CABP, a course of IV/PO treatment with omadacycline has similar clinical efficacy as the with the comparator antibiotic, IV/PO moxifloxacin. The study is designed as a bridging study, to confirm the results of the pivotal global CABP trial in an ethnically different population of Chinese.

NCT ID: NCT06162221 Recruiting - Clinical trials for Non-Small Cell Lung Cancer, NSCLC

Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Start date: January 18, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with each other. The first two subprotocols include the following: Subprotocol A: RMC-6291 + SOC Subprotocol B: RMC-6236 + SOC

NCT ID: NCT06162078 Recruiting - Clinical trials for Maternal Malaria During Pregnancy - Baby Not Yet Delivered

Malaria Burden in Pregnant Women and the Incidence of Pregnancy in a Cohort of Nulligravida

EPI-PAM
Start date: August 25, 2023
Phase:
Study type: Observational [Patient Registry]

The overarching aims of this study are to longitudinally determine the occurrence of pregnancy in a cohort of nulligravida at the community level and to estimate the burden of malaria infection during the course of the pregnancy till delivery.